Last reviewed · How we verify
Phentolamine Opthalmic Solution 0.75%
Phentolamine Opthalmic Solution 0.75% is a Alpha-adrenergic antagonist Small molecule drug developed by Ocuphire Pharma, Inc.. It is currently in Phase 3 development for Presbyopia (age-related loss of accommodation), Intraocular pressure reduction in glaucoma or ocular hypertension (investigational). Also known as: Nyxol.
Phentolamine is an alpha-adrenergic receptor antagonist that blocks norepinephrine signaling in the eye to reduce pupil dilation and improve aqueous humor outflow.
Phentolamine is an alpha-adrenergic receptor antagonist that blocks norepinephrine signaling in the eye to reduce pupil dilation and improve aqueous humor outflow. Used for Presbyopia (age-related loss of accommodation), Intraocular pressure reduction in glaucoma or ocular hypertension (investigational).
At a glance
| Generic name | Phentolamine Opthalmic Solution 0.75% |
|---|---|
| Also known as | Nyxol |
| Sponsor | Ocuphire Pharma, Inc. |
| Drug class | Alpha-adrenergic antagonist |
| Target | Alpha-1 adrenergic receptor, Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Phentolamine works by antagonizing alpha-1 and alpha-2 adrenergic receptors in ocular tissues. By blocking these receptors, it causes miosis (pupil constriction) and may enhance trabecular outflow of aqueous humor, thereby reducing intraocular pressure. This mechanism is relevant for conditions where elevated intraocular pressure contributes to vision loss.
Approved indications
- Presbyopia (age-related loss of accommodation)
- Intraocular pressure reduction in glaucoma or ocular hypertension (investigational)
Common side effects
- Conjunctival hyperemia
- Ocular irritation
- Headache
- Blurred vision
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phentolamine Opthalmic Solution 0.75% CI brief — competitive landscape report
- Phentolamine Opthalmic Solution 0.75% updates RSS · CI watch RSS
- Ocuphire Pharma, Inc. portfolio CI
Frequently asked questions about Phentolamine Opthalmic Solution 0.75%
What is Phentolamine Opthalmic Solution 0.75%?
How does Phentolamine Opthalmic Solution 0.75% work?
What is Phentolamine Opthalmic Solution 0.75% used for?
Who makes Phentolamine Opthalmic Solution 0.75%?
Is Phentolamine Opthalmic Solution 0.75% also known as anything else?
What drug class is Phentolamine Opthalmic Solution 0.75% in?
What development phase is Phentolamine Opthalmic Solution 0.75% in?
What are the side effects of Phentolamine Opthalmic Solution 0.75%?
What does Phentolamine Opthalmic Solution 0.75% target?
Related
- Drug class: All Alpha-adrenergic antagonist drugs
- Target: All drugs targeting Alpha-1 adrenergic receptor, Alpha-2 adrenergic receptor
- Manufacturer: Ocuphire Pharma, Inc. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Presbyopia (age-related loss of accommodation)
- Indication: Drugs for Intraocular pressure reduction in glaucoma or ocular hypertension (investigational)
- Also known as: Nyxol
- Compare: Phentolamine Opthalmic Solution 0.75% vs similar drugs
- Pricing: Phentolamine Opthalmic Solution 0.75% cost, discount & access